Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2023
Conference Publication
More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial
Moore, Elizabeth, Harrison, Simon, Ho, P. Joy, Irving, Adam, King, Tracy, Mccaughan, Georgia, Mcquilten, Zoe, Mollee, Peter, Park, Susanna, Petrie, Dennis, Reynolds, John, Rutherford, Claudia, van Tonder, Tina, Wellard, Cameron, Wood, Erica and Spencer, Andrew (2023). More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000977464.68933.f0
2023
Journal Article
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma
Teh, Benjamin W., Reynolds, Gemma, Slavin, Monica A., Cooley, Louise, Roberts, Matthew, Liu, Eunice, Thursky, Karin, Talaulikar, Dipti, Mollee, Peter, Szabo, Ferenc, Ward, Chris, Chan, Henry, Prince, H. Miles, Harrison, Simon J. and the Medical and Scientific Advisory Group, Myeloma Australia and National Centrefor Infections in Cancer (2023). Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Internal Medicine Journal, 53 (8), 1469-1477. doi: 10.1111/imj.16100
2023
Journal Article
Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography
Ferkh, Aaisha, Tjahjadi, Catherina, Stefani, Luke, Geenty, Paul, Byth, Karen, De Silva, Kasun, Boyd, Anita C., Richards, David, Mollee, Peter, Korczyk, Dariusz, Taylor, Mark S., Kwok, Fiona, Kizana, Eddy, Ng, Arnold C. T. and Thomas, Liza (2023). Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Frontiers in Cardiovascular Medicine, 10 1183485. doi: 10.3389/fcvm.2023.1183485
2023
Journal Article
The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia
Sim, Shirlene, Kalff, Anna, Tuch, Gina, Mollee, Peter, Ho, Joy, Harrison, Simon, Gibbs, Simon, Prince, H. Miles, Spencer, Andrew, Joshua, Douglas, Lee, Cindy, Ling, Silvia, Murphy, Nick, Szabo, Ferenc, Szer, Jeff, Weber, Nicholas, Ward, Christopher, Talaulikar, Dipti, Zannettino, Andrew and Quach, Hang (2023). The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia. Internal Medicine Journal, 53 (5), 819-824. doi: 10.1111/imj.16049
2023
Journal Article
Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia
Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631
2023
Journal Article
Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review
Nicol, Jennifer L., Chong, Jamie E., McQuilten, Zoe K., Mollee, Peter, Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia, 23 (2), 86-96. doi: 10.1016/j.clml.2022.10.003
2023
Journal Article
Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
Mistry, Vijay, Scott, Justin R., Wang, Tzu-Yang, Mollee, Peter, Miles, Kenneth A., Law, W. Phillip and Hapgood, Greg (2023). Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma. Cancer Imaging, 23 (1) 11, 1-11. doi: 10.1186/s40644-023-00520-7
2023
Journal Article
The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population
Tan, Joanne L. C., Wellard, Cameron, Moore, Elizabeth M., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Harrison, Simon James, McDonald, Emma‐Jane, Ho, P. Joy, Prince, H. Miles, Augustson, Bradley M., Campbell, Philip, McQuilten, Zoe K., Wood, Erica M., Spencer, Andrew and Myeloma and Related Diseases Registry Investigators (2023). The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. British Journal of Haematology, 200 (2), e17-e21. doi: 10.1111/bjh.18536
2022
Journal Article
Current approaches to the diagnosis and management of amyloidosis
Taylor, Mark S., Sidiqi, Hasib, Hare, James, Kwok, Fiona, Choi, Bo, Lee, Darren, Baumwol, Jay, Carroll, Antonia S., Vucic, Steve, Neely, Pat, Korczyk, Dariusz, Thomas, Liza, Mollee, Peter, Stewart, Graeme J. and Gibbs, Simon D. J. (2022). Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 52 (12), 2046-2067. doi: 10.1111/imj.15974
2022
Conference Publication
A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)
Roussel, Murielle, Mollee, Peter, Huart, Antoine, Sidiqi, Hasib, Horvath, Noemi, Karlin, Lionel, Jacquet, Caroline, Morel, Pierre, Leyronnas, Cecile, Bender, Sebastien, Bridoux, Frank, Jaccard, Arnaud and Gibbs, Simon D. (2022). A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP). 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166337
2022
Conference Publication
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji K., Bahlis, Nizar Jacques, Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Pei, Huiling, Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2022). Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-165524
2022
Conference Publication
An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trial
Nicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2022). An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trial. COSA's 49th Annual Scientific Meeting Equitable Cancer Care for All: Gender, Identity, Culture, Geography, and Disease Should Not Matter, Brisbane, QLD, Australia, 2–4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13868
2022
Conference Publication
76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failure
Rickard, Claire, Larsen, Emily, Marsh, Nicole, McGrail, Matthew, Ullman, Amanda, Kleidon, Tricia, Chan, Ray, Byrnes, Joshua, Mollee, Peter, Paterson, David, Chopra, Vineet, Stone, Leanne, Tapsall, Doreen, Keogh, Samantha, Gavin, Nicole, McCarthy, Sandie, Alexandrou, Evan, Choudhury, M.A., Corley, Amanda, Schults, Jessica, Ray-Barruel, Gillian and Geoffrey Playford, E. (2022). 76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failure. 2022 ACIPC International Conference, Sydney, NSW Australia, 13 - 16 November 2022. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.idh.2022.09.034
2022
Journal Article
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Landgren, Ola, Weisel, Katja, Rosinol, Laura, Touzeau, Cyrille, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Shu, Natalie, Hu, Xuguang, Li, Chuang and Usmani, Saad Z. (2022). Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. British Journal of Haematology, 198 (6), 988-993. doi: 10.1111/bjh.18233
2022
Journal Article
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
McQuilten, Zoe, Wellard, Cameron, Moore, Elizabeth, Augustson, Bradley, Bergin, Krystal, Blacklock, Hilary, Harrison, Simon, Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rosengarten, Brian, Walker, Patricia, Wood, Erica, Spencer, Andrew and Australian and New Zealand Myeloma and Related Diseases Registry (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology, 198 (5), 830-837. doi: 10.1111/bjh.18324
2022
Journal Article
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study
Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, María Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica ... Wechalekar, Ashutosh D. (2022). Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study. American Journal of Hematology, 97 (6), 719-730. doi: 10.1002/ajh.26536
2022
Journal Article
An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial
Nicol, Jennifer L., Woodrow, Carmel, Cunningham, Brent J., Mollee, Peter, Weber, Nicholas, Smith, Michelle D., Nicol, Andrew J., Gordon, Louisa G., Hill, Michelle M. and Skinner, Tina L. (2022). An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial. Current Oncology, 29 (2), 901-923. doi: 10.3390/curroncol29020077
2022
Journal Article
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Joy Ho, P., Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang and Spencer, Andrew (2022). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica, 107 (1), 321-325. doi: 10.3324/haematol.2021.278655
2022
Conference Publication
Predictors of outcomes in patients with ATTRwt cardiac amyloidosis
Mew, T., Mollee, P. and Korczyk, D. (2022). Predictors of outcomes in patients with ATTRwt cardiac amyloidosis. 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Gold Coast, QLD Australia, 11-14 August 2022. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2022.06.115
2022
Journal Article
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Sanchorawala, Vaishali, Boccadoro, Mario, Gertz, Morie, Hegenbart, Ute, Kastritis, Efstathios, Landau, Heather, Mollee, Peter, Wechalekar, Ashutosh and Palladini, Giovanni (2022). Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid, 29 (1), 1-7. doi: 10.1080/13506129.2021.2002841
Funding
Past funding
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: